Article

Song, JM, Kim, YC, Barlow, PG, Hossain, MJ, Park, KM, Donis, RO et al.. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res 88: 244-247

Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA.
Antiviral research (Impact Factor: 3.94). 11/2010; 88(2):244-7. DOI: 10.1016/j.antiviral.2010.09.001
Source: PubMed

ABSTRACT To develop a more effective vaccination method against H5N1 virus, we investigated the immunogenicity and protective efficacy after skin vaccination using microneedles coated with influenza virus-like particles containing hemagglutinin derived from A/Vietnam/1203/04 H5N1 virus (H5 VLPs). A single microneedle vaccination of mice with H5 VLPs induced increased levels of antibodies and provided complete protection against lethal challenge without apparent disease symptoms. In contrast, intramuscular injection with the same vaccine dose showed low levels of antibodies and provided only partial protection accompanied by severe body weight loss. Post-challenge analysis suggested that improved protection was associated with lower lung viral titers and enhanced generation of recall antibody secreting cells by microneedle vaccination. Thus, this study provides evidence that skin delivery of H5 VLP vaccines using microneedles designed for self-administration induces improved protection compared to conventional intramuscular immunization.

Download full-text

Full-text

Available from: Yeu-Chun Kim, Sep 03, 2015
0 Followers
 · 
125 Views
 · 
49 Downloads
  • Source
    • "In addition, the administration of VLP vaccines via microneedles was shown to induce superior levels of recall immune responses compared to conventional intramuscular immunization [29]. Influenza VLPs expressing the HA subunit were coated on solid metal microneedles and manually applied onto the skin of mice, which induced comparable antibody responses to intramuscular administration, and full protection against viral challenge [30, 31]. Moreover, another study compared the immune responses elicited by low-dose microneedle and low-dose intramuscular routes, which reported that the low-dose microneedle induced higher immune responses that were similar to the serological antibody titers produced by high-dose intramuscular route [32]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In today's medical industry, the range of vaccines that exist for administration in humans represents an eclectic variety of forms and immunologic mechanisms. Namely, these are the live attenuated viruses, inactivated viruses, subunit proteins, and virus-like particles for treating virus-caused diseases, as well as the bacterial-based polysaccharide, protein, and conjugated vaccines. Currently, a new approach to vaccination is being investigated with the concept of DNA vaccines. As an alternative delivery route to enhance the vaccination efficacy, microneedles have been devised to target the rich network of immunologic antigen-presenting cells in the dermis and epidermis layers under the skin. Numerous studies have outlined the parameters of microneedle delivery of a wide range of vaccines, revealing comparable or higher immunogenicity to conventional intramuscular routes, overall level of stability, and dose-sparing advantages. Furthermore, recent mechanism studies have begun to successfully elucidate the biological mechanisms behind microneedle vaccination. This paper describes the current status of microneedle vaccine research.
    01/2014; 3(1):42-49. DOI:10.7774/cevr.2014.3.1.42
  • [Show abstract] [Hide abstract]
    ABSTRACT: The electromagnetic interference appearing in electronic circuits due to the coupling of high-power radio frequency radiation has been considered. Rectification processes in nonlinear elements have been taken into account. The results of theoretical calculation, computer simulation and experimental investigation are presented.
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: The main public health strategy for reducing the influenza burden is annual vaccination. However, because the immune response in the elderly and frail subjects is known to be less vigorous than in younger adults, novel strategies have been explored in the last decade to augment immune response after immunization. These have included an increased dosage, multiple dose vaccinations, use of vaccine adjuvants and more efficient routes of vaccine delivery. AREAS COVERED: This review discusses recent advances in intradermally administered influenza vaccines with particular attention to immunogenicity and safety data from clinical trials performed using appropriate injection systems which, combining consistent injection depth and volume, safety, simplicity and ease-of-use, allowed large scale evaluation. EXPERT OPINION: Substantial experience has been accumulated with Intanza® 9 and Intanza 15 μg/IDflu® 15 μg, administered using BD's Soluvia™ device, and are the first intradermal trivalent inactivated split-virion influenza vaccines to be licensed for use in 18 - 59 year adults and in elderly people, respectively. Clinical data showed that they are safe and immunogenic and can offer significant advantages in terms of higher acceptability, higher immunogenicity in the elderly and dose-sparing in adults younger than 60 years when compared with intramuscularly administered vaccine.
    Expert opinion on biological therapy 03/2011; 11(3):415-27. DOI:10.1517/14712598.2011.557658 · 3.65 Impact Factor
Show more